Hudson Bay Capital Management
CRMD icon

Hudson Bay Capital Management’s CorMedix CRMD Stock Holding History

Hudson Bay Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-158,326
Closed -$339K – 417
2017
Q2 		$339K Buy
+158,326
New +$542K 0.01% 467

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Hudson Bay Capital Management's CRMD Position: Q3 2017 in Review

Hudson Bay Capital Management sold out of CorMedix (CRMD) in Q3 2017, closing a stake of 158,326 shares — an estimated $339K sold.

Hudson Bay Capital Management first reported a position in CRMD in Q2 2017 and held it in 1 quarter. The position peaked at $339K in Q2 2017. 33 funds tracked by Wall St. Rank hold CRMD as of Q3 2017.

  • Hudson Bay Capital Management reported no remaining CorMedix position as of Q3 2017 after selling out during the quarter.
  • Hudson Bay Capital Management sold 158,326 CorMedix shares in Q3 2017, an estimated $339K.
  • Hudson Bay Capital Management first reported a position in CorMedix in Q2 2017 and held it in 1 quarter.
  • Hudson Bay Capital Management's CorMedix position peaked at $339K in Q2 2017.
  • 33 funds tracked by Wall St. Rank held CorMedix as of Q3 2017.

Based on Hudson Bay Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.